Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13054MR)

This product GTTS-WQ13054MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13054MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14820MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ8692MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ12388MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ12600MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ6900MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ3528MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ8396MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ8574MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW